Biologic Drugs With Established Pharmaceutical Class: Programmed Death Receptor-1 Blocking Antibody
✉ Email this page to a colleague
Biologic Drugs With Established Pharmaceutical Class: Programmed Death Receptor-1 Blocking Antibody
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | For Injection | 125514 | 2014-09-04 | ⤷ Subscribe | ⤷ Subscribe |
Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 2014-12-22 | ⤷ Subscribe | ⤷ Subscribe |
Genentech, Inc. | TECENTRIQ | atezolizumab | Injection | 761034 | 2016-05-18 | ⤷ Subscribe | ⤷ Subscribe |
Glaxosmithkline Llc | JEMPERLI | dostarlimab-gxly | Injection | 761174 | 2021-04-22 | ⤷ Subscribe | ⤷ Subscribe |
Bristol-myers Squibb Company | OPDUALAG | nivolumab and relatlimab-rmbw | Injection | 761234 | 2022-03-18 | ⤷ Subscribe | ⤷ Subscribe |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Patent Expiration |